AbbVie (ABBV) won an expected, but much-needed boost on Wednesday when the Food and Drug Administration approved its new Skyrizi medication for treating psoriasis. The question now is the extent to which this move will help the drug maker compensate for the impending loss of patent protection on Humira, a franchise product that is prescribed for the same malady, among other things.

The answer seems to be that Skyrizi — which will launch next month with a $59,000 list price — will help, but only so much.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • psoriasis is an incurable (for now) chronic disease. biologics like humira are highly effective but over time their efficacy fades, so this is a market of churn. once it is widely available as a biosimilar, humira will cement its place as the first line biologic, but there’s always going to be plenty of opportunity for subsequent treatments. the efficacy and dosing schedule make this treatment highly attractive, even if its when the efficacy of humira inevitably fades over time.

  • I wonder how often psoriasis drugs can be avoided by finding the cause. I had plaque psoriasis in 2017 that lasted nearly a year. I only figured out what it was after thin flakes of skin up to about a centimeter long began peeling off. I tried to think what I was doing differently that may have caused this. I realized I’d been eating 4 to 6 oz. of cashews daily as a protein source, and I remembered that cashews contain urushiol which is a powerful antigen (same one as in poison oak and poison ivy). I stopped eating cashews, and the psoriasis peaked in the two following days. After that, it diminished until it was gone. If I’d gone for a drug treatment, I’d probably still be on the drug. I’ll probably never eat another cashew or the other foods that contain urushiol (mangoes and pink and green peppercorns).

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy